ArticleAnnals of medicine and surgery (2012)2025
Chronic liver disease and radiation-induced second primary liver malignancy: a retrospective cohort based on SEER database 2010-2021.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cirrhotic patients are at a high risk of developing radiation-induced liver toxicities despite the modern safe radiation delivery techniques due to the low liver tolerance. Recent studies demonstrated a potential risk of second primary malignancies (SPMs) following radiotherapy (RT) with further investigations for strategies to decrease RT-induced SPMs. However, it is insufficiently addressed if developing liver SPMs is a serious adverse event following RT for cirrhotic patients. Thus, we aimed to quantitatively assess the risk of gastrointestinal (GI) and liver SPMs following RT in patients with liver fibrosis. Methods: The SEER*Stat beta software version 9.0.32 was used to obtain and analyze the data of patients with chronic liver disease diagnosed from 2010 to 2021. We sub-grouped patients according to the history of receiving RT for prior cancer treatment into two groups and excluded patients with unknown RT administration history. Results: We observed 215 cirrhotic patients developed GI SPMs (O/E = 2.76, Conclusion: Cirrhotic patients who received RT before had an increased risk for GI SPMs by three folds and a 12-fold increased risk for liver SPMs. However, who received no RT had an 8-fold increased risk for liver SPM. Thus, screening for HCC in cirrhotic patients exposed to RT is a must for early detection and better management outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.